Retatrutide
GLP1
+4
Aug 4, 2026
•
12 min read
Retatrutide Won Twice. The Heart Data Didn't.
TRIUMPH-2 and TRIUMPH-3 both hit — 20.8% in type 2 diabetes, 22.6% with established cardiovascular disease. Then there's the MACE table.
GLP1
+3
Jul 28, 2026
•
4 min read
The Triple Agonist, in Plain Numbers
Retatrutide is posting some of the largest weight-loss numbers the incretin class has seen. Here's what the data actually says — and the two things to watch before the headline. Free cheat sheet inside.
GLP1
+3
Mar 27, 2026
•
15 min read
What Semaglutide Teaches Us About How GLP-1 Regulates Body Weight
It's not the injection site. It's not gut GLP-1. It's not thermogenesis. The pharmacokinetics of semaglutide across multiple trials offer a surprisingly clean window into how this molecule — and this biology — actually works.
